Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Plans To Spin Off Diabetes Care Business

Executive Summary

BD believes the independent new company will create shareholder value and is part of the BD 2025 growth strategy. 

You may also be interested in...



Meet Embecta! Becton Dickinson Completes Diabetes Spin-Off

Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.

Polen: BD Aiming For Higher Growth Spaces And More Tuck-Ins

BD stressed the continued pursuit of an innovation-driven growth strategy as it announced fiscal 2021 sales of $20bn spurred by its pandemic response effort.

Exec Chat: Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

Medtech Insight talked with Moshe Shoham about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel